Reviews/P2Y12 Antiplatelets/Prasugrel reduces MACE vs clopidogrel in ACS patients undergoing PCI
Pras · P2Y12-PRAS-01 · v2
Borderline: within 4 points of the Established/Likely boundary, so a re-grade could land either side.
One large, carefully run head-to-head trial [1] found that prasugrel prevented more heart attacks, strokes and cardiovascular deaths than clopidogrel in patients treated with stents after a heart attack or unstable chest pain. The same trial's analysis of the most severe heart-attack patients pointed the same way [2]. But that STEMI analysis is part of the same study, not a separate confirmation, so the finding rests heavily on a single trial. In older patients given a lower dose of prasugrel, the advantage disappeared [6], and in a small, non-randomised group of patients in shock the only signal was on survival, not the combined heart-outcome measure [14]. The benefit in the main trial also came with more serious bleeding, and overall survival was no different. The panel treated the claim as well supported for standard dosing in this population while flagging that it leans on one trial and does not hold unconditionally.
The corpus contains one direct, large, double-blind randomised test of the claim: in 13,608 ACS patients with scheduled PCI, the composite of cardiovascular death, non-fatal MI or non-fatal stroke fell from 12.1% on clopidogrel to 9.9% on prasugrel (HR 0.81, 95% CI 0.73 to 0.90) [1], with parallel reductions in MI and stent thrombosis. The STEMI cohort of that same trial echoed the result (HR 0.79 at 15 months) but shares NCT00097591 and is not independent [2]. A head-to-head comparison using low-dose 5 mg prasugrel in patients aged over 74 found no difference (HR 1.17, 95% CI 0.819 to 1.67) [6]. A 145-patient cardiogenic-shock registry reported lower all-cause mortality with prasugrel (HR 0.51) but no difference in MI or stent thrombosis [14]. The contested point: The division is whether a single pivotal trial [1], restated in its own STEMI subset [2], is enough to treat the effect as a general property of prasugrel-versus-clopidogrel in ACS-PCI. The low-dose elderly comparison [6] and the small shock registry [14] either reverse or fail to reproduce the composite benefit, so the signal is strongest for standard 10 mg dosing and thin on independent replication.
All 16 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from P2Y12 Antiplatelets, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The positive signal rests on a single pivotal trial: [1] and [2] share NCT00097591, so they are the same study, not independent replication.
Effect is not uniform: with low-dose prasugrel in elderly patients the MACE point estimate reverses (HR 1.17, [6]), so the claim holds for standard 10mg dosing, not as an unqualified statement.
Where it remains uncertain. The benefit rests on a single trial, is accompanied by increased major bleeding with no overall mortality difference [1], and is absent with low-dose prasugrel in the elderly (HR 1.17) [6].
Aleatory
The low-dose elderly estimate spans benefit to harm (HR 1.17, 95% CI 0.819 to 1.67) [6], so chance variation alone leaves its true direction unresolved.
Epistemic
Only one trial tests the claim; [2] is its STEMI cohort under the same NCT00097591, so no independent replication exists in the corpus.
The load-bearing papers from a corpus of 16, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Pivotal RCT evidence: significant MACE reduction in ACS-PCI
“The primary efficacy end point occurred in 12.1% of patients receiving clopidogrel and 9.9% of patients receiving prasugrel (hazard ratio for prasugrel vs. clopidogrel, 0.81; 95% confidence interval [CI], 0.73 to 0.90; P<0.001).”
Panel auditInternal validity: high · scope of inference: Moderate-to-high-risk ACS patients with scheduled PCI over 6-15 months.Key limitations: increased major and fatal bleeding with prasugrel · overall mortality not different
STEMI cohort of the same trial; consistent MACE reduction (not independent of [1])
“At 30 days, 115 (6.5%) individuals assigned prasugrel had met the primary endpoint compared with 166 (9.5%) allocated clopidogrel (hazard ratio 0.68 [95% CI 0.54-0.87]; p=0.0017). This effect continued to 15 months (174 [10.0%] vs 216 [12.4%]; 0.79 [0.65-0.97]; p=0.0221).”
Panel auditInternal validity: high · scope of inference: STEMI patients undergoing PCI, a subset of the broader ACS-PCI claim population.Key limitations: STEMI-only subset not full ACS spectrum · increased TIMI major bleeding after CABG with prasugrel
Qualifier: no MACE benefit with low-dose prasugrel in elderly ACS-PCI
“no significant difference was observed with prasugrel vs clopidogrel with regard to the primary endpoint (HR 1.17; CI 0.819–1.67; p=0.39, Figure 1A)”
Panel auditInternal validity: medium · scope of inference: Elderly (>74 years) ACS patients on low-dose prasugrel undergoing complex PCI.Key limitations: post-hoc subgroup · low-dose prasugrel · composite includes bleeding and re-hospitalisation
Supportive registry signal in cardiogenic shock; mortality favours prasugrel, MACE components not different
“All-cause mortality was lower in prasugrel- vs clopidogrel-treated patients (30 % vs 50.5%, HR: 0.51, 95% CI [0.29-0.92], p=0.025). No significant differences in prasugrel- vs clopidogrel-treated patients were observed for the occurrence of MI (p=0.233)”
Panel auditInternal validity: low · scope of inference: AMI patients complicated by cardiogenic shock undergoing primary PCI.Key limitations: observational with confounding by indication · no MACE composite reported · small cardiogenic-shock sample
4 of 16 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
One high-quality pivotal trial strongly supports the claim for standard-dose ACS-PCI, but single-trial dependence and marginal heterogeneity warrant a conservative Likely rather than Established.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
No independent replication at standard dose. The entire positive signal is one trial [1] restated in its own STEMI subset [2]; without a separate trial the effect size cannot be checked for reproducibility. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: An independent, adequately powered double-blind RCT of standard-dose prasugrel versus clopidogrel in ACS-PCI with the same composite endpoint.
Open question: Does the standard-dose prasugrel MACE benefit replicate in an independent randomised trial? Why it is still open: Both on-claim randomised results [1] and [2] come from the same study (NCT00097591), so no independent confirmation exists in the corpus.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19